Explain this page
Arphra AIPlain-English read on Nurix Therapeutics, Inc.’s valuation06-08today
- Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy11d
- Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy11d
- Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?12d
- Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcript13d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $33.00 (+88.03%)
Candlestick · 1Y
Open in chart workstation →NRIX
17.55+2.69%H 18.91L 14.01MA50 15.97MA200 —Avg vol 1.3M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.51% | +2.27% | +0.29% | +21.62% | -9.26% | -7.49% | +46.49% | +72.23% | -39.19% | -7.68% | -7.68% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$17.34
1 sh
Bid
$16.96
100 sh
Ask
$17.63
60 sh
Spread
$0.670
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Technology+2.51%
- Communication Services+1.85%
- Utilities+1.35%
- Consumer Cyclical+0.30%
- Consumer Defensive-0.30%
- Energy-0.45%
- Industrials-0.48%
- Basic Materials-0.66%
- Financial Services-0.67%
- Real Estate-0.99%
- Healthcare-1.51%
Top industries (issuer's industry highlighted)
- Biotechnology+0.28%
- Oil & Gas Energy+8.53%
- Business Equipment & Supplies+5.82%
- Semiconductors+5.24%
- Electronic Gaming & Multimedia+5.23%
- Advertising Agencies-5.20%
- Medical - Equipment & Services+5.08%
- Grocery Stores-4.35%
- Financial - Mortgages+4.08%
- Broadcasting+4.00%
- Computer Hardware-3.67%
- Internet Content & Information+3.58%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapyglobenewswire.com·Jun 11, 2026
- Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapyglobenewswire.com·Jun 11, 2026
- Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?zacks.com·Jun 09, 2026
- Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcriptseekingalpha.com·Jun 08, 2026
- Nurix Therapeutics to Participate in Upcoming Investor Conferencesglobenewswire.com·May 13, 2026
- Nurix Therapeutics to Participate in Upcoming Investor Conferencesglobenewswire.com·May 13, 2026
- Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congressglobenewswire.com·May 12, 2026
- Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congressglobenewswire.com·May 12, 2026
Recent analyst activity
DB- Jun 11, 2026GradeBuy → BuyH.C. Wainwright Reiterates Buy Rating on Nurix (NRIX)H.C. Wainwright
- Jun 09, 2026GradeBuy → BuyUBS Reiterates Buy Rating on Nurix (NRIX)UBS
- Jun 09, 2026PT$23.00UBS Reiterates Buy Rating on Nurix (NRIX)UBS
- Jun 09, 2026PT$32.00Nurix Therapeutics price target raised to $32 from $30 at BTIGBTIG
- Jun 09, 2026GradeBuy → BuyNurix Therapeutics price target raised to $32 from $30 at BTIGBTIG
- Jun 08, 2026PT$32.00Nurix Therapeutics price target raised to $32 from $30 at TruistTruist Financial
- Jun 08, 2026GradeBuy → BuyNurix Therapeutics price target raised to $45 from $41 at JefferiesJefferies
- Jun 08, 2026PT$45.00Nurix Therapeutics price target raised to $45 from $41 at JefferiesJefferies
- Jun 08, 2026GradeOutperform → OutperformOppenheimer on Nurix (NRIX): 'A Big Check for a Big Opportunity'Oppenheimer
- Jun 08, 2026PT$34.00Nurix Therapeutics price target raised to $34 from $26 at NeedhamNeedham
- Jun 08, 2026GradeBuy → BuyNurix Therapeutics price target raised to $34 from $26 at NeedhamNeedham
- Jun 08, 2026GradeOutperform → OutperformNurix (NRIX) trades up 20%, RBC says agreement with Roche removes some overhangs, 'We remain buyers'RBC Capital
Peers
No peer list available for NRIX.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|